- Home
- PHAR vs EH Comparison
PHAR vs EH Comparison
Compare PHAR & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | EH |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Netherlands | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PHAR | EH |
|---|---|---|
| Price | $16.39 | $13.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $30.00 | $21.85 |
| AVG Volume (30 Days) | 21.0K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | $60,400,607.00 |
| Revenue This Year | $24.80 | $13.66 |
| Revenue Next Year | $6.84 | $75.95 |
| P/E Ratio | $3,084.39 | ★ N/A |
| Revenue Growth | ★ 26.78 | 23.39 |
| 52 Week Low | $7.50 | $12.71 |
| 52 Week High | $18.12 | $29.76 |
Technical Indicators
Market Signals| Indicator | PHAR | EH |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 31.26 |
| Support Level | $15.76 | $13.51 |
| Resistance Level | $18.12 | $14.55 |
| Average True Range (ATR) | 0.83 | 0.53 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 28.81 | 28.27 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.